Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from BridgeBio Pharma ( (BBIO) ).
On May 7, 2026, BridgeBio Pharma, Inc. filed an automatic shelf registration statement on Form S-3ASR with the U.S. Securities and Exchange Commission and entered into a new Equity Distribution Agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC. The arrangement establishes an at-the-market program under which BridgeBio may, at its discretion, issue and sell up to $500 million of common stock through the agents on a best-efforts basis, with commissions of up to 3% of gross proceeds.
The agreement allows BridgeBio to raise capital flexibly over time via sales on Nasdaq or other existing markets without any obligation to sell a specific amount, while the company and agents retain the right to suspend or terminate the program. In connection with this new facility, BridgeBio and the same agents agreed to terminate their prior equity distribution agreement dated May 4, 2023, as of May 7, 2026, signaling a refreshed structure for the company’s ongoing access to equity financing.
The most recent analyst rating on (BBIO) stock is a Buy with a $116.00 price target. To see the full list of analyst forecasts on BridgeBio Pharma stock, see the BBIO Stock Forecast page.
Spark’s Take on BBIO Stock
According to Spark, TipRanks’ AI Analyst, BBIO is a Neutral.
The score is held back primarily by weak financial performance (large losses, heavy cash burn, negative equity) and bearish technicals. These are partially offset by a relatively positive earnings-call outlook driven by strong Atruby commercialization, multiple late-stage pipeline successes, and guidance for improving cash dynamics over time; valuation provides limited support given negative earnings and no dividend.
To see Spark’s full report on BBIO stock, click here.
More about BridgeBio Pharma
BridgeBio Pharma, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of therapies for genetic diseases and other serious conditions. The company’s shares are listed on the Nasdaq Global Select Market, giving it access to public equity markets to support its research, development and commercialization activities.
Average Trading Volume: 2,576,035
Technical Sentiment Signal: Buy
Current Market Cap: $13.21B
For detailed information about BBIO stock, go to TipRanks’ Stock Analysis page.